Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer

Mattia Luca Piccinelli1,2 · Stefano Luzzago1,12 · Giulia Marvaso3,12 · Ekaterina Laukhtina4,5 · Noriyoshi Miura5,6 · Victor M. Schuettfort5,7 · Keiichiro Mori5,8 · Alberto Colombo10 · Matteo Ferro1 · Francesco A. Mistretta1,12 · Nicola Fusco11,12 · Giuseppe Petralia9,12 · Barbara A. Jereczek-Fossa3,12 · Shahrokh F. Shariat4,5,13,14,15,16,17,18 · Pierre I. Karakiewicz19 · Ottavio de Cobelli1,12 · Gennaro Musi1,12

Received: 23 January 2022 / Accepted: 27 February 2022 / Published online: 26 March 2022
© The Author(s) 2022, corrected publication 2022

Abstract
Purpose To test any-cause discontinuation and ISUP GG upgrading rates during Active Surveillance (AS) in patients that underwent previous negative biopsies (PNBs) before prostate cancer (PCa) diagnosis vs. biopsy naïve patients.

Methods Retrospective analysis of 961 AS patients (2008–2020). Three definitions of PNBs were used: (1) PNBs status (biopsy naïve vs. PNBs); (2) number of PNBs (0 vs. 1 vs. ≥ 2); (3) histology at last PNB (no vs. negative vs. HGPIN/ASAP). Kaplan–Meier plots and multivariable Cox models tested any-cause and ISUP GG upgrading discontinuation rates.

Results Overall, 760 (79.1%) vs. 201 (20.9%) patients were biopsy naïve vs. PNBs. Specifically, 760 (79.1%) vs. 138 (14.4%) vs. 63 (6.5%) patients had 0 vs. 1 vs. ≥ 2 PNBs. Last, 760 (79.1%) vs. 134 (13.9%) vs. 67 (7%) patients had no vs. negative PNB vs. HGPIN/ASAP. PNBs were not associated with any-cause discontinuation rates. Conversely, PNBs were associated with lower rates of ISUP GG upgrading: (1) PNBs vs. biopsy naïve (HR: 0.6, p = 0.04); (2) 1 vs. 0 PNBs (HR: 0.6, p = 0.1) and 2 vs. 0 PNBs, (HR: 0.5, p = 0.1); (3) negative PNB vs. biopsy naïve (HR: 0.7, p = 0.3) and HGPIN/ASAP vs. biopsy naïve (HR: 0.4, p = 0.04). However, last PNB ≤ 18 months (HR: 0.4, p = 0.02), but not last PNB > 18 months (HR: 0.8, p = 0.5) were associated with lower rates of ISUP GG upgrading.

Conclusion PNBs status is associated with lower rates of ISUP GG upgrading during AS for PCa. The number of PNBs and time from last PNB to PCa diagnosis (≤ 18 months) appear also to be critical for patient selection.

Keywords Active surveillance · Previous negative biopsies · Biopsy naïve · Any-cause discontinuation · Upgrading

Introduction
Active surveillance (AS) represents a valid management strategy for patients with very low- and low-volume intermediate-risk prostate cancer (PCa) [1–5]. However, previous series showed a risk of disease misclassification, at the time of AS beginning that ranges from 22 to 33% [2]. Moreover, even the most stringent AS criteria are not able to fully discriminate patients affected by clinically significant PCa (csPCa) [6]. Novel tools have been tested to reduce disease misclassification rates. For example, confirmatory biopsies or multiparametric magnetic resonance imaging (mpMRI) have been employed in daily practice [7–14].

Previous negative biopsies (PNBs), before PCa diagnosis, have been associated with lower rates of adverse findings at radical prostatectomy (RP) [15–19].

We hypothesized lower rates of disease progression during AS in PNBs patients, relative to their biopsy naïve counterparts.

To address this void, we focussed on a large contemporary series of AS patients and we tested two commonly used AS outcomes, namely: (1) any-cause discontinuation; (2) discontinuation due to upgrading.

Mattia Luca Piccinelli and Stefano Luzzago: co-authorship shared.
Materials and methods

Study population

This retrospective single-institution data analysis was approved by the Institutional Review Board of the European Institute of Oncology.

Overall, 961 patients with PCa were enrolled in AS between 2008 and 2020. AS inclusion criteria were the following: prostate specific antigen (PSA) ≤ 10 ng/ml; clinical stage (cT) cT1c/cT2a; International Society of Urological Pathology Grade Group (ISUP GG) 1 PCa with ≤ 3 positive cores or ISUP GG2 PCa with pattern 4 < 10% in a single core; PSA-density (PSAD) < 0.2 ng/ml/ml. AS protocol consisted of: repeated PSA testing (every 6 months for 5 years and annually thereafter); clinical assessment every 12 months and repeated surveillance biopsies scheduled at 12, 36 and 84 months. Since 2015, confirmatory mpMRI was employed in AS protocol and offered to all patients at AS begin (≤ 6 months from diagnostic biopsy). Here, all patients with Prostate Imaging Reporting and Data System (PI-RADS) score ≥ 3 underwent confirmatory targeted biopsies, as previously reported [20, 21]. Additionally, repeated mpMRI scans were performed before surveillance biopsies. Here, 1–3 targeted-cores were additionally taken in patients with positive mpMRIs (PI-RADS score ≥ 3) [22–24].

Patients were switched to active treatment (AT) due to: (1) ISUP GG upgrading (ISUP GG ≥ 2 with > 10% of pattern 4); (2) volume upstaging (> 3 positive cores with ISUP GG1 PCa); (3) rising PSA; (4) suspicious extra-prostatic extension at mpMRI; (5) patient preference.

Variables of interest

We tested the association between PNBs and AS outcomes. Specifically, PNBs were defined as all negative prostate samplings performed before the diagnostic biopsy that allowed for AS begin. Three different definitions of PNBs were used: (1) PNBs status (biopsy naïve vs. PNBs); (2) number of PNBs (0 [biopsy naïve] vs. 1 vs. ≥ 2); (3) histology at last PNB before the diagnosis of PCa that allowed for AS begin (biopsy naïve vs. negative vs. high-grade prostatic intraepithelial neoplasia [HGPIN] and/or atypical small acinar proliferation [ASAP]).

Statistical analyses

We focussed on two AS outcomes: (1) any-cause discontinuation; (2) discontinuation due to ISUP GG upgrading (ISUP GG ≥ 2 with > 10% of pattern 4).

Differences in medians and proportions were evaluated by, respectively, the Kruskal–Wallis and chi-square tests. First, Kaplan–Meier (KM) plots tested any-cause discontinuation and ISUP GG upgrading rates over time. Second, multivariable Cox regression models tested associations between patient’s or tumour characteristics and rates of AS discontinuation.

R software environment was used in all statistical analyses and graphics (version 3.4.3). All tests were two sided with a level of significance set at $p < 0.05$.

Results

Descriptive analyses (Table 1)

Overall, 760 (79.1%) vs. 201 (20.9%) patients were biopsy naïve vs. PNBs. Specifically, 760 (79.1%) vs. 138 (14.4%) vs. 63 (6.5%) patients had 0 (biopsy naïve) vs. 1 vs. ≥ 2 PNBs. Last, according to histology at last PNB, 760 (79.1%) vs. 134 (13.9%) vs. 67 (7%) patients had no PNBs (biopsy naïve) vs. negative PNB vs. HGPIN/ASAP.

PNBs patients were older (median: 65 vs. 64 years, $p = 0.04$) and had higher median PSA at AS begin (6.5 vs. 5.6 ng/ml, $p < 0.001$), relative to their biopsy naïve counterparts. Moreover, PNBs patients had less frequently two (20.9 vs. 27.9%) or three (4.5 vs. 13.7%) positive cores at diagnostic biopsy ($p < 0.001$).

Findings at follow-up

Median (IQR: interquartile range) time follow-up was 35 (18–63) months. During AS, 32.8 vs. 44.1%, 16.4 vs. 15% and 10 vs. 6.8% PNBs vs. biopsy naïve patients underwent 1, 2, ≥ 3 surveillance biopsies, respectively ($p = 0.03$).

Overall, 34.3 vs. 34.5% ($p = 0.9$) PNBs vs. biopsy naïve patients experienced any-cause discontinuation. Conversely, 10.9 vs. 15.8% ($p = 0.1$) PNBs vs. biopsy naïve patients had ISUP GG upgrading (Supplementary Table 1).

In KM plots, 3-year rates of any-cause and ISUP GG upgrading survival were, respectively, 70 vs. 65% ($p = 0.04$; Fig. 1a) and 88 vs. 82% ($p = 0.02$; Fig. 1b) in PNBs vs. biopsy naïve patients. Moreover, 3-year rates of any-cause and ISUP GG upgrading survival were, respectively, 65% vs. 69% vs. 69% ($p = 0.4$; Fig. 1c) and 82% vs. 87% vs. 90% ($p = 0.08$; Fig. 1d) in patients with 0 vs. 1 vs. ≥ 2 PNBs. Last, 3-year rates of any-cause and ISUP GG upgrading survival were, respectively, 65% vs. 66% vs. 75% ($p = 0.2$; Fig. 1e) and 82% vs. 85% vs. 93% ($p = 0.04$; Fig. 1f) in biopsy naïve patients vs. patients with negative PNBs vs. patients with HGPIN/ASAP.
In multivariable Cox regression models (Table 2), PNBs were not associated with lower rates of any-cause discontinuation, regardless of PNBs definition. Conversely, in multivariable Cox regression models, PNBs were associated with lower rates of ISUP GG upgrading: (1) PNBs vs. biopsy naïve, Hazard Ratio (HR): 0.6 (95% confidence interval [CI]: 0.4–0.9, \( p = 0.04 \)); (2) 1 vs. 0 PNBs, HR:0.6 (95% CI:0.4–1.1, \( p = 0.1 \)) and 2 vs. 0 PNBs, HR:0.5 (95% CI:0.3–1.1, \( p = 0.1 \)); (3) negative PNB vs. biopsy naïve, HR:0.7 (95% CI:0.4–1.3, \( p = 0.3 \)) and HGPIN/ASAP vs. biopsy naïve, HR:0.4 (95% CI:0.2–0.9, \( p = 0.04 \)).

**Sensitivity analysis: time between last PNB and AS begin**

We performed a sensitivity analysis to test the association between time from last PNB to AS begin and the two mentioned outcomes. Median (IQR) time from last PNB to AS begin was 19 (9–40) months. In KM plots, 3-year rates of any-cause and ISUP GG upgrading survival were, respectively, 65% vs. 65% vs. 74% (\( p = 0.1 \); Supplementary Fig. 1a) and 82% vs. 82% vs. 93% (\( p = 0.02 \); Supplementary Fig. 1b) in biopsy naïve patients vs. last PNB > 18 months vs. last PNB ≤ 18 months.

In multivariable Cox regression models (Supplementary Table 2), neither last PNB ≤ 18 months (HR:0.7 [95% CI:0.5–1.05, \( p = 0.09 \)]) nor last PNB > 18 months (HR:1.1 [95% CI:0.7–1.5, \( p = 0.8 \)]) were associated with lower rates of any-cause discontinuation. Conversely, last PNB ≤ 18 months (HR:0.4 [95% CI:0.2–0.9, \( p = 0.02 \)]), but not last PNB > 18 months (HR:0.8 [95% CI:0.4–1.5, \( p = 0.5 \)]) were associated with lower rates of ISUP GG upgrading, relative to biopsy naïve patients.
Discussion

Patient selection at AS begin represents a critical step. To date, novel confirmatory exams have been developed and implemented in daily practice [7–14, 25–29]. However, most of these tools are usually performed several months after PCa diagnosis [7–11]. Moreover, possible side effects or elevated costs [25–27] limit patient compliance. In consequence, there is an urgent need to find immediately available and low-cost tools to confirm patient eligibility to AS. We focussed on the association between PNBs and two commonly used AS outcomes, namely any-cause and ISUP GG upgrading discontinuation, in a large series of AS patients. Specifically, the protective effect of PNBs was tested in a systematic fashion and accordingly to three PNBs definitions, namely: (1) PNBs status (biopsy naïve vs. PNBs); (2) number of PNBs (0 [biopsy naïve] vs. 1 vs. ≥ 2); (3) histology at last PNB (biopsy naïve vs. negative histology vs. HGPIN/ASAP). Our results showed several important findings.

First, we observed similar rates of any-cause discontinuation between biopsy naïve and PNBs patients, regardless of PNBs definition. However, when ISUP GG upgrading (ISUP GG ≥ 2 with > 10% of pattern 4) rates were tested, PNBs patients were at lower risk of upgrading (HR:0.6; \( p = 0.04 \)), relative to their biopsy naïve counterparts. Moreover, while we were unable to reach statistical significance (\( p = 0.1 \)) due to low number of patients, a gradual increase in the protective association between PNBs and ISUP GG upgrading rates was observed with an increasing number of PNBs (HR:0.6 for 1 PNB; HR:0.5 for ≥ 2 PNBs). Last, histology at last PNB was also associated with ISUP GG upgrading rates. Specifically, only patients with HGPIN/ASAP (HR:0.4; \( p = 0.04 \)), but not patients with negative findings at last PNB (HR:0.7; \( p = 0.3 \)), were at lower risk of ISUP GG upgrading over time. Our results are supported by the non-negligible follow-up time (35 months) and by the use of multivariable Cox regression models that were fully adjusted for all available patients and tumour characteristics.

To the best of our knowledge, we are the first to specifically focus on the role of PNBs on AS outcomes. Indeed, several previous authors tested the association between findings at confirmatory biopsy (≤ 1 year after PCa diagnosis) and AS outcomes over time [7–11], without considering prostate samplings before AS begin. Due to the novelty of our analysis, only hypothetical considerations could justify
Table 2 Separate multivariable Cox-regression models predicting (a) any-cause AS discontinuation rates and (b) ISUP GG upgrading rates, according to PNBs status (yes vs. no), number of PNBs at AS begin (0 [biopsy naïve] vs. 1 vs. ≥ 2) and histology at last PNB before AS diagnostic biopsy (biopsy naïve vs. negative vs. HGPIN/ASAP).

| Hazard ratio (HR) [95% CI] | p value |
|---------------------------|---------|
| (a) Any-cause AS discontinuation rates |
| PNBs (yes vs. no) | 0.9 (0.6–1.2) | 0.4 |
| Number of PNBs |
| 0 (biopsy naïve) | Ref. |
| 1 | 0.9 (0.65–1.2) | 0.5 |
| ≥2 | 0.9 (0.5–1.4) | 0.5 |
| Histology at last PNB |
| Biopsy naïve | Ref. |
| Negative | 0.9 (0.7–1.3) | 0.7 |
| HGPIN/ASAP | 0.8 (0.5–1.2) | 0.3 |
| (b) ISUP GG upgrading rates |
| PNBs (yes vs. no) | 0.6 (0.4–0.9) | 0.04 |
| Number of PNBs |
| 0 (biopsy naïve) | Ref. |
| 1 | 0.6 (0.4–1.1) | 0.1 |
| ≥2 | 0.5 (0.3–1.1) | 0.1 |
| Histology at last PNB |
| Biopsy naïve | Ref. |
| Negative | 0.7 (0.4–1.3) | 0.3 |
| HGPIN/ASAP | 0.4 (0.2–0.9) | 0.04 |

All models are adjusted for clinical characteristics and biopsy findings at patient enrolment: age (years), PSA (ng/ml), cT (cT1c vs. cT2a), confirmatory mpMRI (no vs. yes), number of positive cores at biopsy (1 vs. 2 vs. 3), ISUP GG at biopsy (1 vs. 2). Bold values indicate statistical significance p < 0.05.

AS active surveillance, PNBs previous negative biopsies, HGPIN high-grade prostatic intraepithelial neoplasia, ASAP atypical small acinar proliferation, PSA prostate specific antigen, cT clinical T stage, mpMRI multiparametric magnetic resonance imaging, ISUP GG international society of urological pathology grade group, CI confidence interval.

Our findings. Specifically, we can hypothesize that PNBs patients could be at lower risk of disease misclassification at AS enrolment. This hypothesis is supported by several previous manuscripts that reported lower rates of csPCa at RP in patients that underwent multiple prostate samplings before surgery [15–19]. Indeed, Rosenbaum et al. and Dja-yan et al. observed decreasing rates of extra-prostatic PCa, aggressive tumour histology and lymph node metastases with an increasing number of prostate biopsies before RP [16, 17]. Our results could be used for patients counselling at AS recruitment. Specifically, the use of AS confirmatory tests could be modulated according to PNBs status. Indeed, confirmatory biopsies could be recommended for all patients that were biopsy naïve before PCa diagnosis. Conversely, due to the retrospective nature of the current analysis, the modulation of AS follow-up schemes, in which PNBs patients could be less frequently submitted to repeated biopsies, should be tested in other multi-institutional and ideally prospective studies.

Second, when we repeated our analyses after considering time from last PNB to AS begin, we observed that only patients with last PNB performed ≤ 18 months (HR:0.4; p = 0.02), but not patients with last PNB > 18 months (HR:0.8; p = 0.5) were at lower risk of ISUP GG upgrading. We can argue that only patients with at least one PNB ≤ 18 months are at lower risk of disease misclassification at AS begin. Indeed, prostate samplings performed > 18 months could not be representative of patient situation at the moment of PCa diagnosis. Moreover, these findings could also justify the observed association between histology at last PNB and ISUP GG upgrading rates, where only patients with HGPIN/ASAP, but not patients with negative PNB, were at lower risk of ISUP GG upgrading. Indeed, during the study period, the EAU guidelines recommended prompt prostate re-biopsy for all patients diagnosed with HGPIN/ASAP [1]. In consequence, it is possible that the observed association between HGPIN/ASAP at last PNB and lower rates of ISUP GG upgrading over time is not related to biopsy history but is a product of time from last PNB.

Taken together, PNBs history appears to be a useful tool for confirming patient eligibility to AS. Specifically, PNBs patients are at lower risk of disease upgrading during AS, relative to their biopsy naïve counterparts. This protective association appears to be even stronger in patients with a history of multiple PNBs before PCa diagnosis. However, time from last PNB to AS begin should be considered as a critical factor. Results from other series, with a specific focus on RP findings after AS, are warranted before recommending AS protocols modifications.

Despite its novelty our study has limitations. First, the current data are retrospective and influenced by inherent selection bias. Second, the long-time span (2008–2020) of the current analysis could limit the applicability of our findings in contemporary clinical practice. However, our multivariable Cox regression models were also adjusted for mpMRI performance at AS begin, as recommended by EAU guidelines [1]. In consequence, our results are not a product of different AS protocols used for PNBs vs. biopsy naïve patients. Indeed, during follow-up, no meaningful differences in number of repeated biopsies or repeated mpMRI scans were observed between PNBs vs. biopsy naïve patients. Third, we were unable to stratify PNBs patients according to the type of prostate biopsies performed before PCa diagnosis. Specifically, information about PNBs schemes, techniques (systematic vs. targeted cognitive vs. targeted fusion vs. RM-guided) or approaches (transrectal vs. transperineal) are missing. However, the median (IQR) number of cores performed during PNBs was...
13 (12–15) and, in consequence, prostate undersampling is unlikely. Fourth, we used specific AS inclusion criteria. In consequence, our results could not be applicable in other AS protocols. Therefore, external validation of our findings is needed for implementing the systematic consideration of PNBs status in AS protocols.

**Conclusion**

PNBs status is associated with lower rates of ISUP GG upgrading during AS for PCa. The number of PNBs and time from last PNB to PCa diagnosis (≤18 months) appear also to be critical for patient selection.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00345-022-03983-8.

**Acknowledgements** This work was partially supported by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds.

**Author contributions** MLP: protocol/project development, data collection or management, manuscript writing/editing. SL: protocol/project development, data collection or management, data analysis, manuscript writing/editing. GM: manuscript writing/editing. VMS: manuscript writing/editing. NM: manuscript writing/editing. EL: manuscript writing/editing. AC: manuscript writing/editing. MF: manuscript writing/editing. BAJ: protocol/project development. SFS: protocol/project development. PIK: protocol/project development. OC: protocol/project development. GM: protocol/project development.

**Funding** Open access funding provided by Università degli Studi di Milano within the CRUI-CARE Agreement.

**Declarations**

**Conflict of interest** All authors declare to have no potential conflict of interest.

**Ethics approval** This retrospective data analysis was approved by the Institutional Review Board of the European Institute of Oncology and was conducted according to the ethical guidelines of the Declaration of Helsinki.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Consent to publish** Patients signed informed consent regarding publishing their data and photographs. Stefano Luzzago had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Mottet N, Bastian P, Bellmunt J et al (2020) Eau-Eanm-Estro-Eusr-Siog: guidelines on prostate cancer. In: European Association of Urology. Eur Assoc Urol Guidelines Office, Arnhem, The Netherlands, pp 1–182.
2. Bokhorst LP, Valdagni R, Rannikko A et al (2016) A decade of active surveillance in the prias study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 70:954–960. https://doi.org/10.1016/j.eururo.2016.06.007
3. Klotz L, Vespreni D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277. https://doi.org/10.1200/JCO.2014.55.1192
4. Moschini M, Carroll PR, Eggenger SE et al (2017) Low-risk prostate cancer: identification, management, and outcomes. Eur Urol 72:238–249. https://doi.org/10.1016/j.eururo.2017.03.009
5. Tosoian JJ, Trock BJ, Landis P et al (2011) Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 29:2185–2190. https://doi.org/10.1200/JCO.2010.32.8112
6. Lee MC, Dong F, Stephenson AJ et al (2010) The epstein criteria predict for organ-confined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 58:90–95. https://doi.org/10.1016/j.eururo.2009.10.025
7. Adamy A, Yee DS, Matsushita K et al (2011) Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 185:477–482. https://doi.org/10.1016/j.juro.2010.09.095
8. Kearns JT, Faino AV, Newcomb LF et al (2018) Role of surveillance biopsy with no cancer as a prognostic marker for reclassification: results from the canary prostate active surveillance study[formula presented]. Eur Urol 73:706–712. https://doi.org/10.1016/j.eururo.2018.01.016
9. Cary KC, Cowan JE, Sanford M et al (2014) Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol 66:337–342. https://doi.org/10.1016/j.eururo.2013.08.060
10. Wong LM, Alibhai SMH, Trotter G et al (2014) A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression. Eur Urol 66:406–413. https://doi.org/10.1016/j.eururo.2013.04.038
11. Al Otaibi M, Ross P, Fahmy N et al (2008) Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 113:286–292. https://doi.org/10.1002/cncr.23575
12. Bryant RJ, Yang B, Philippou Y et al (2018) Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification? BJU Int 122:794–800. https://doi.org/10.1111/bju.14248
13. Luzzago S, de Cobelli O, Mistretta FA et al (2020) MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like
Authors and Affiliations

Mattia Luca Piccinelli1,2, Stefano Luzzago1,2, Giulia Marvaco3,12, Ekaterina Laukhtina4,5, Noriyoshi Miura5,6, Victor M. Schuettfort5,7, Keiichiro Mori5,8, Alberto Colombo10, Matteo Ferro1, Francesco A. Mistretta1,12, Nicola Fusco11,12, Giuseppe Petralia9,12, Barbara A. Jereczek-Fossa3,12, Shahrokh F. Shariat4,5,13,14,15,16,17,18, Pierre I. Karakiewicz19, Ottavio de Cobelli11,12, Gennaro Musi1,12

1 Department of Urology, IEO European Institute of Oncology, IRCCS, Via Giuseppe Ripamonti 435, Milan, Italy
2 Università degli Studi di Milano, Milan, Italy
3 Department of Radiotherapy, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy
4 Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia
5 Department of Urology, Medical University of Vienna, Vienna, Austria
6 Department of Urology, Eihe University Graduate School of Medicine, Ehime, Japan
7 Department of Urology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
8 Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
9 Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, IEO European Institute of Oncology IRCCS, 20141 Milan, Italy
10 Division of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy
11 Department of Pathology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy
12 Department of Oncology and Haemat Oncology, Università Degli Studi Di Milano, 20122 Milan, Italy
13 Research Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan
14 Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA
15 Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic
16 Department of Urology, Weill Cornell Medical College, New York, NY, USA
17 Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
18 European Association of Urology Research Foundation, Arnhem, Netherlands
19 Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada